Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In Eyecare

Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand despite recent market underperformance. ALC demonstrates steady revenue growth, improved core EPS guidance, and a pipeline of innovative products targeting high-need clinical niches like glaucoma and macular disease. Balance sheet strength is evident with investment-grade ratings and the lowest D/E ratio among peers, reducing leverage risk and enhancing the risk profile.

Seeking Alpha • Oct 21, 2026

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.

Business Wire • Oct 20, 2026

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

Business Wire • Oct 16, 2026

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.

Zacks Investment Research • Sep 4, 2026

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.

Business Wire • Sep 3, 2026

Alcon: A Re-Rating In Eyesight

Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.

Seeking Alpha • Sep 3, 2026

Alcon Prices EUR 500 Million Senior Notes Offering

GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.

Business Wire • Aug 26, 2026

Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy

Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.

Seeking Alpha • Aug 17, 2026

Bill Ackman Moves Stocks. These 5 Prove It.

Netflix, Visa and other stocks rose on the news that Bill Ackman was investing in them. The billionaire focuses on buying what he views as high-quality growth companies.

Barrons • Aug 14, 2026

Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.

Netflix is once again an apple in Bill Ackman's eye, as the streamer was among six stocks Pershing Square added in the last six months.

Market Watch • Aug 13, 2026